Sightera Biosciences Closes €3M to Advance Oncology Program

The big picture: Sightera Biosciences, a Belgian techbio company, just closed a €3 million pre-seed round led by Entourage, Anacura, and QBIC. The funding will help grow its AI drug discovery platform, which uniquely starts by training models on data from patients resistant to treatment.

Why it matters:

• Patient-first approach: Sightera reverses the traditional AI drug discovery paradigm, beginning with patient-derived biology from treatment-resistant cases to design new molecules.
• Addressing unmet needs: This method targets the most challenging diseases, like advanced cancer and fibrosis, where standard treatments fail, aiming to develop truly effective therapies.
• Market demand: The rising cost of traditional drug development and expiring patents drive pharmaceutical companies to seek faster, more efficient AI-native platforms.

How it works:

• Extreme biology: Sightera collects samples from patients with treatment-resistant conditions, growing them into organoids for high-throughput drug screens.
• Data-driven design: The platform generates long-term data on how resistant diseases react to therapies, which its AI then uses to design small molecules for desired biological responses.
• Molecular glue oncology: The pre-seed funding will specifically advance its lead program, SIGHT001, a molecular-glue oncology candidate, towards preclinical selection.

The catch: The AI drug discovery market is crowded, with companies like Graph Therapeutics also using patient tissue, and larger players such as Isomorphic Labs, Chai Discovery, Recursion Pharmaceuticals, Insilico Medicine, and Exscientia focusing on broad AI models. While Sightera’s patient-first approach is novel, the ultimate challenge will be clinical validation and demonstrating superior efficacy compared to established or competing AI-driven methods.